Cite
HARVARD Citation
Furze, R. et al. (2022). Phase 1 and preclinical profiling of ESM‐HDAC391, a myeloid‐targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia. British journal of clinical pharmacology. 88 (12), pp. 5238-5256. [Online].